220 related articles for article (PubMed ID: 28012176)
1. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
3. Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals.
Villemagne VL; Doré V; Chong L; Kassiou M; Mulligan R; Feizpour A; Taylor J; Roesner M; Miller T; Rowe CC
J Alzheimers Dis; 2024; 97(3):1463-1475. PubMed ID: 38250767
[TBL] [Abstract][Full Text] [Related]
4. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
[TBL] [Abstract][Full Text] [Related]
5. Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
Gómez C; Alimajstorovic Z; Othonos N; Winter DV; White S; Lavery GG; Tomlinson JW; Sinclair AJ; Odermatt A
Br J Pharmacol; 2024 Mar; 181(5):698-711. PubMed ID: 37740611
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH; Stone JA; Crumley TM; Wenning L; Zheng W; Yan K; Yang AY; Sun L; Cilissen C; Ramael S; Hermanowski-Vosatka A; Langdon RB; Gottesdiener KM; Wagner JA; Lai E
Br J Clin Pharmacol; 2013 Dec; 76(6):917-31. PubMed ID: 23594227
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
8. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
[TBL] [Abstract][Full Text] [Related]
10. Green tea and one of its constituents, Epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Hintzpeter J; Stapelfeld C; Loerz C; Martin HJ; Maser E
PLoS One; 2014; 9(1):e84468. PubMed ID: 24404164
[TBL] [Abstract][Full Text] [Related]
11. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
12. Analgesic effects of ASP3662, a novel 11β-hydroxysteroid dehydrogenase 1 inhibitor, in rat models of neuropathic and dysfunctional pain.
Kiso T; Sekizawa T; Uchino H; Tsukamoto M; Kakimoto S
Br J Pharmacol; 2018 Oct; 175(19):3784-3796. PubMed ID: 30006998
[TBL] [Abstract][Full Text] [Related]
13. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Courtney R; Stewart PM; Toh M; Ndongo MN; Calle RA; Hirshberg B
J Clin Endocrinol Metab; 2008 Feb; 93(2):550-6. PubMed ID: 17986636
[TBL] [Abstract][Full Text] [Related]
14. Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects.
Bellaire S; Walzer M; Wang T; Krauwinkel W; Yuan N; Marek GJ
Clin Transl Sci; 2019 May; 12(3):291-301. PubMed ID: 30740895
[TBL] [Abstract][Full Text] [Related]
15. Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Sun D; Wang M; Wang Z
Curr Top Med Chem; 2011; 11(12):1464-75. PubMed ID: 21510838
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Bianzano S; Heise T; Jungnik A; Schepers C; Schölch C; Gräfe-Mody U
Clin Diabetes Endocrinol; 2021 Aug; 7(1):16. PubMed ID: 34391480
[TBL] [Abstract][Full Text] [Related]
17. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor in rats.
Zheng Z; Seo H; Kwak HJ; Kim KY; Ahn JH; Bae MA; Song JS
Arch Pharm Res; 2016 Apr; 39(4):492-498. PubMed ID: 26780247
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
Gibbs JP; Emery MG; McCaffery I; Smith B; Gibbs MA; Akrami A; Rossi J; Paweletz K; Gastonguay MR; Bautista E; Wang M; Perfetti R; Daniels O
J Clin Pharmacol; 2011 Jun; 51(6):830-41. PubMed ID: 20663992
[TBL] [Abstract][Full Text] [Related]
20. Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Bianzano S; Schepers C; Wolff M; Heise T; Plum-Moerschel L
Exp Clin Endocrinol Diabetes; 2022 Dec; 130(12):773-782. PubMed ID: 36343645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]